Real‐world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV‐1 aged over 50 years who are virologically suppressed

Documenti analoghi

• Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort
  di: Inés Suárez‐García, et al.
  Pubblicazione: (2025)
• Impact of HBV serological status on HIV virological efficacy of two‐drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir
  di: Pierluigi Francesco Salvo, et al.
  Pubblicazione: (2025)
• Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies
  di: C. Katlama, et al.
  Pubblicazione: (2024)
• Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin‐based regimen: A retrospective observational case series
  di: Yanyun Dou, et al.
  Pubblicazione: (2024)
• Biomarkers of inflammation and coagulation predict non‐AIDS‐defining events in a prospective cohort of virologically suppressed people living with HIV
  di: Maria Saumoy, et al.
  Pubblicazione: (2025)